Fennec Pharmaceuticals, Inc. (FENC)
11.74
+0.34
(+2.98%)
USD |
NASDAQ |
Aug 25, 16:00
11.74
0.00 (0.00%)
After-Hours: 19:59
Fennec Pharmaceuticals EPS Diluted (Quarterly) : 0.0542 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0542 |
| March 31, 2026 | 0.0056 |
| December 31, 2025 | -0.165 |
| September 30, 2025 | -0.0229 |
| June 30, 2025 | -0.1139 |
| March 31, 2025 | -0.0422 |
| December 31, 2024 | -0.059 |
| September 30, 2024 | -0.2095 |
| June 30, 2024 | -0.2034 |
| March 31, 2024 | 0.4129 |
| December 31, 2023 | -0.0999 |
| September 30, 2023 | -0.0702 |
| June 30, 2023 | -0.2058 |
| March 31, 2023 | -0.2279 |
| December 31, 2022 | -0.2601 |
| September 30, 2022 | -0.3098 |
| June 30, 2022 | -0.1947 |
| March 31, 2022 | -0.1421 |
| December 31, 2021 | -0.1702 |
| September 30, 2021 | -0.1609 |
| June 30, 2021 | -0.1539 |
| March 31, 2021 | -0.182 |
| December 31, 2020 | -0.1245 |
| September 30, 2020 | -0.2422 |
| June 30, 2020 | -0.2071 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.1923 |
| December 31, 2019 | -0.1814 |
| September 30, 2019 | -0.0909 |
| June 30, 2019 | -0.2377 |
| March 31, 2019 | -0.132 |
| December 31, 2018 | -0.15 |
| September 30, 2018 | -0.1449 |
| June 30, 2018 | -0.14 |
| March 31, 2018 | -0.09 |
| December 31, 2017 | -0.1244 |
| September 30, 2017 | -0.15 |
| June 30, 2017 | -0.11 |
| March 31, 2017 | -0.06 |
| December 31, 2016 | -0.08 |
| September 30, 2016 | -0.04 |
| June 30, 2016 | -0.06 |
| March 31, 2016 | -0.04 |
| December 31, 2015 | -0.05 |
| September 30, 2015 | -0.01 |
| June 30, 2015 | -0.02 |
| March 31, 2015 | 0.01 |
| December 31, 2014 | 0.14 |
| September 30, 2014 | 0.03 |
| June 30, 2014 | -0.09 |
| March 31, 2014 | -0.33 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Abeona Therapeutics, Inc. | -0.3539 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 1.973M |
| Revenue (Quarterly) | 17.87M |
| Total Expenses (Quarterly) | 15.90M |
| Enterprise Value | 358.14M |
| Gross Profit Margin (Quarterly) | 95.97% |
| Profit Margin (Quarterly) | 11.04% |
| Earnings Yield | -1.09% |
| Normalized Earnings Yield | -0.7044 |